ABBVIE
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
- Conditions
- Interventions
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT02692703
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 378
- Registration Number
- NCT02691494
- Locations
- 🇺🇸
University of California, Los Angeles /ID# 149760, Los Angeles, California, United States
🇺🇸Mount Vernon Clinical Res, LLC /ID# 144297, Atlanta, Georgia, United States
🇺🇸Clinical Trial Investigators /ID# 152470, Tustin, California, United States
Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT02688790
- Locations
- 🇺🇸
Children's Mercy Kansas City, Kansas City, Missouri, United States
🇺🇸Mary Birch Hospital for Women and Newborns, San Diego, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients
- Conditions
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 59
- Registration Number
- NCT02687828
- Locations
- 🇰🇷
Pusan Nat Univ Yangsan Hosp /ID# 169243, Yangsan-si,, Gyeongsangnamdo, Korea, Republic of
🇰🇷Ajou University Hospital /ID# 147938, Suwon-si, Gyeonggido, Korea, Republic of
🇰🇷Kyungpook National Univ Hosp /ID# 147937, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 577
- Registration Number
- NCT02684357
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 560
- Registration Number
- NCT02684370
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 661
- Registration Number
- NCT02675426
- Locations
- 🇪🇸
Hospital Clin Univ San Carlos /ID# 138993, Madrid, Spain
🇺🇸Houston Institute for Clin Res /ID# 138716, Houston, Texas, United States
🇧🇪AZ Sint Lucas /ID# 141338, Brugge, Belgium
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 342
- Registration Number
- NCT02674568
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 507
- Registration Number
- NCT02672852
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation
- Conditions
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 158
- Registration Number
- NCT02669940